Cargando…
The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy
The impressive clinical success of cancer immunotherapy has motivated the continued search for new targets that may serve to guide potent effector functions in an attempt to efficiently kill malignant cells. The intracellular proteome is an interesting source for such new targets, such as neo-antige...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818436/ https://www.ncbi.nlm.nih.gov/pubmed/36611821 http://dx.doi.org/10.3390/cells12010027 |
_version_ | 1784864985409650688 |
---|---|
author | Arman, Inbar Haus-Cohen, Maya Reiter, Yoram |
author_facet | Arman, Inbar Haus-Cohen, Maya Reiter, Yoram |
author_sort | Arman, Inbar |
collection | PubMed |
description | The impressive clinical success of cancer immunotherapy has motivated the continued search for new targets that may serve to guide potent effector functions in an attempt to efficiently kill malignant cells. The intracellular proteome is an interesting source for such new targets, such as neo-antigens and others, with growing interest in their application for cell-based immunotherapies. These intracellular-derived targets are peptides presented by MHC class I molecules on the cell surface of malignant cells. These disease-specific class I HLA–peptide complexes can be targeted by specific TCRs or by antibodies that mimic TCR-specificity, termed TCR-like (TCRL) antibodies. Adoptive cell transfer of TCR engineered T cells and T-cell-receptor-like based CAR-T cells, targeted against a peptide-MHC of interest, are currently tested as cancer therapeutic agents in pre-clinical and clinical trials, along with soluble TCR- and TCRL-based agents, such as immunotoxins and bi-specific T cell engagers. Targeting the intracellular proteome using TCRL- and TCR-based molecules shows promising results in cancer immunotherapy, as exemplified by the success of the anti-gp100/HLA-A2 TCR-based T cell engager, recently approved by the FDA for the treatment of unresectable or metastatic uveal melanoma. This review is focused on the selection and isolation processes of TCR- and TCRL-based targeting moieties, with a spotlight on pre-clinical and clinical studies, examining peptide-MHC targeting agents in cancer immunotherapy. |
format | Online Article Text |
id | pubmed-9818436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98184362023-01-07 The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy Arman, Inbar Haus-Cohen, Maya Reiter, Yoram Cells Review The impressive clinical success of cancer immunotherapy has motivated the continued search for new targets that may serve to guide potent effector functions in an attempt to efficiently kill malignant cells. The intracellular proteome is an interesting source for such new targets, such as neo-antigens and others, with growing interest in their application for cell-based immunotherapies. These intracellular-derived targets are peptides presented by MHC class I molecules on the cell surface of malignant cells. These disease-specific class I HLA–peptide complexes can be targeted by specific TCRs or by antibodies that mimic TCR-specificity, termed TCR-like (TCRL) antibodies. Adoptive cell transfer of TCR engineered T cells and T-cell-receptor-like based CAR-T cells, targeted against a peptide-MHC of interest, are currently tested as cancer therapeutic agents in pre-clinical and clinical trials, along with soluble TCR- and TCRL-based agents, such as immunotoxins and bi-specific T cell engagers. Targeting the intracellular proteome using TCRL- and TCR-based molecules shows promising results in cancer immunotherapy, as exemplified by the success of the anti-gp100/HLA-A2 TCR-based T cell engager, recently approved by the FDA for the treatment of unresectable or metastatic uveal melanoma. This review is focused on the selection and isolation processes of TCR- and TCRL-based targeting moieties, with a spotlight on pre-clinical and clinical studies, examining peptide-MHC targeting agents in cancer immunotherapy. MDPI 2022-12-21 /pmc/articles/PMC9818436/ /pubmed/36611821 http://dx.doi.org/10.3390/cells12010027 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Arman, Inbar Haus-Cohen, Maya Reiter, Yoram The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy |
title | The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy |
title_full | The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy |
title_fullStr | The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy |
title_full_unstemmed | The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy |
title_short | The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy |
title_sort | intracellular proteome as a source for novel targets in car-t and t-cell engagers-based immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818436/ https://www.ncbi.nlm.nih.gov/pubmed/36611821 http://dx.doi.org/10.3390/cells12010027 |
work_keys_str_mv | AT armaninbar theintracellularproteomeasasourcefornoveltargetsincartandtcellengagersbasedimmunotherapy AT hauscohenmaya theintracellularproteomeasasourcefornoveltargetsincartandtcellengagersbasedimmunotherapy AT reiteryoram theintracellularproteomeasasourcefornoveltargetsincartandtcellengagersbasedimmunotherapy AT armaninbar intracellularproteomeasasourcefornoveltargetsincartandtcellengagersbasedimmunotherapy AT hauscohenmaya intracellularproteomeasasourcefornoveltargetsincartandtcellengagersbasedimmunotherapy AT reiteryoram intracellularproteomeasasourcefornoveltargetsincartandtcellengagersbasedimmunotherapy |